Lilly's amylin-tirzepatide combo shows weight loss gains, more side effects in trial
Eli Lilly's mid-stage trial data on combining an experimental amylin drug with Zepbound is drawing varied coverage, with some outlets emphasizing the weight loss gains and others focusing on side effects and unresolved questions about a separate triple-hormone drug.
What happened
Eli Lilly reported that adding its experimental amylin drug, eloralintide, to tirzepatide (Zepbound) helped trial participants lose up to 23% of their body weight in a mid-stage study.23
The combination therapy showed more side effects than Zepbound alone, and STAT reported high discontinuation rates that raise questions about tolerability.24
Lilly plans to begin Phase 3 trials on the combination regimen by the end of the year.3
Separately, Ars Technica reported on retatrutide, a triple-hormone drug simulating GLP-1, GIP, and glucagon, describing it as the most powerful obesity drug yet, with trial participants losing up to 25% of their weight.5
What's agreed
Reported consistently by outlets in more than one region.
Where accounts differ
Each account is attributed to who makes it. We do not judge between them.
Which drug or combination represents the most significant advance
MarketWatch and CNBC, reporting on Lilly's eloralintide-tirzepatide combination
Adding Lilly's amylin drug eloralintide to Zepbound (tirzepatide) helped people lose up to 23% of their weight in a mid-stage trial.23
Ars Technica, reporting on a separate drug, retatrutide
Retatrutide, a triple-hormone drug simulating GLP-1, GIP, and glucagon, is described as the most powerful obesity drug, with trial participants losing up to 25% of their weight.5
New Scientist, describing tirzepatide combination therapy generally
Tirzepatide, already the most potent weight-loss drug available, becomes even more effective when combined with a complementary medicine, producing what the outlet calls astonishing results.1
Severity and significance of side effects
MarketWatch
The eloralintide-tirzepatide combination had more side effects than Zepbound alone.2
STAT
High discontinuation rates in the trial raise questions about the combination therapy's tolerability.4
CNBC
Reports on the trial results and Lilly's Phase 3 plans without highlighting side effects as a central concern.3
How it's framed
What each perspective puts first, based on headlines and summaries.
| Perspective | How it reads | What it puts first |
|---|---|---|
| US business and trade press covering Lilly's specific trialNorth America | MarketWatch, CNBC and STAT focus on Eli Lilly's mid-stage trial data for combining eloralintide with tirzepatide, reporting both the weight loss figures and tolerability concerns, with STAT giving most weight to discontinuation rates.234 | mid-stage trial results, Phase 3 plans, tolerability and discontinuation |
| UK science mediaEurope | New Scientist frames tirzepatide combination therapy in broadly enthusiastic terms, calling the results astonishing without detailing side effects.1 | potency of tirzepatide, astonishing results |
| US technology and science pressNorth America | Ars Technica highlights a different drug, retatrutide, describing it as the most powerful obesity treatment based on trial weight loss figures.5 | triple-hormone mechanism, most powerful obesity drug |
What the coverage leaves out
- None of the outlets reviewed reported the full trial size, duration, or detailed safety data beyond mentioning increased side effects or discontinuation rates.
- None of the outlets reviewed clarified whether retatrutide (S5) and the eloralintide-tirzepatide combination (S2, S3, S4) are part of the same or different research programs.
- None of the outlets reviewed included independent medical expert commentary on the trial results.
- None of the outlets reviewed reported regulatory status or expected timeline for approval of these combination therapies.
Why it matters
GLP-1 drugs like tirzepatide have become widely used for weight loss, and pharmaceutical companies are testing combination therapies to further boost efficacy.13
What to watch
- Results of Lilly's planned Phase 3 trials on the eloralintide-tirzepatide combination.
- Further data on side effects and discontinuation rates from ongoing or future trials.
Sources (5)
Every outlet we drew on, grouped by where it is based. Read the originals for the full reporting.
North America
- 2MarketWatchUSPrivate
- 3CNBCUSPrivate
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- 4STATUSPrivate
- 5Ars TechnicaUSPrivate
Most powerful obesity drug yet: People lost up to 25% of weight in trial
Europe
- 1New ScientistGBPrivate
‘Astonishing’ weight loss when GLP-1 drug used with second medication